Related Experiment Video
Updated: Jun 14, 2025
04:53
An In Vitro Approach to Photodynamic Therapy
Published on: August 17, 2018
8.7K
Preclinical Evaluation of an Integrin αvβ6-Targeted Photodynamic Therapy
Hua Zhang1, Tanushree Ganguly1, Rebecca Harris2
1Department of Biomedical Engineering, University of California, Davis, California 95616, United States.
Bioconjugate Chemistry
|June 13, 2025
Summary
This study developed a novel photosensitizer targeting integrin αvβ6 for enhanced photodynamic therapy (PDT). The targeted photosensitizer demonstrated improved tumor selectivity and potent anti-cancer efficacy in preclinical models.
Area of Science:
- Biochemistry
- Oncology
- Photomedicine
Background:
- Photodynamic therapy (PDT) efficacy is limited by photosensitizer (PS) tumor selectivity.
- Integrin αvβ6 is overexpressed in various cancers, correlating with poor survival.
Purpose of the Study:
- To develop a photosensitizer with improved tumor selectivity by targeting integrin αvβ6.
- To evaluate the photochemical, photophysical, and therapeutic properties of the novel targeted PS.
Main Methods:
- Conjugation of an integrin αvβ6-targeting peptide (ABM-5G) to a water-soluble PS (IRDye700DX).
- In vitro assessment of αvβ6-selective binding, internalization, and phototoxicity.
- In vivo evaluation of tumor accumulation and therapeutic efficacy in xenograft mouse models.
Main Results:
- The resulting conjugate (IR700-ABM-5G) retained excellent photochemical properties.
- Demonstrated αvβ6-selective binding and phototoxicity in vitro.
- Showed enhanced tumor accumulation and significant suppression of αvβ6-expressing tumor growth in vivo.
Conclusions:
- IR700-ABM-5G exhibits potent and selective photodynamic therapy efficacy against αvβ6-expressing tumors.
- This targeted approach offers a promising strategy for treating αvβ6-associated cancers.
